What are the appropriate indications, dosing regimens, contraindications, and monitoring parameters for prasterone (dehydroepiandrosterone, DHEA) therapy?

Prasterone (DHEA) Use: Indications, Dosing, and Monitoring

Prasterone (DHEA) should NOT be used routinely in most clinical scenarios, with two narrow exceptions: (1) intravaginal prasterone 6.5 mg daily for moderate-to-severe dyspareunia due to vulvovaginal atrophy in postmenopausal women, and (2) a 6-month trial of oral DHEA 25-50 mg daily in women with primary adrenal insufficiency who have persistent low libido, depression, or fatigue despite optimized glucocorticoid and mineralocorticoid replacement. 1, 2

Primary Indication: Vulvovaginal Atrophy in Postmenopausal Women

Intravaginal prasterone is FDA-approved and represents the strongest evidence-based use. 3, 4, 5

Dosing Regimen

• Dose: 6.5 mg intravaginal pessary/suppository
• Frequency: Once daily at bedtime
• Duration: Continuous use as needed for symptom control
• Onset: Significant improvement typically seen by 4 weeks, with continued benefit through 52 weeks 4, 6

Mechanism and Safety

Intravaginal prasterone works through local tissue conversion to estrogens and androgens without clinically significant systemic absorption. Serum estradiol and testosterone levels remain within normal postmenopausal ranges (estradiol <9.3 pg/mL, testosterone <0.26 ng/mL), avoiding systemic hormonal effects. 7 This local action makes it safer than systemic estrogen therapy, particularly for women with estrogen-sensitive conditions.

Monitoring

• Clinical assessment: Improvement in dyspareunia severity, vaginal dryness, and sexual function
• No routine hormonal monitoring required due to minimal systemic absorption 7
• Adverse effects to monitor: Vaginal discharge (most common), application site reactions

Comparative Effectiveness

Recent evidence suggests intravaginal DHEA may be superior to vaginal estradiol for severe dyspareunia (OR 3.4 for improvement), though estradiol shows better improvement in objective vaginal atrophy signs. 6 This makes DHEA particularly valuable for women with predominant pain symptoms.

---

Secondary Indication: Primary Adrenal Insufficiency in Women

The Endocrine Society provides conditional support (weak recommendation, grade 2) for a trial of DHEA in select women with primary adrenal insufficiency. 2 This is NOT routine therapy but reserved for specific symptomatic patients.

Patient Selection Criteria

DHEA trial is appropriate ONLY when ALL of the following are present:

• Confirmed primary adrenal insufficiency (PAI)
• Female sex (premenopausal or postmenopausal)
• Persistent symptoms of low libido, depressive symptoms, and/or low energy
• Already optimized glucocorticoid and mineralocorticoid replacement
• Symptoms significantly impacting quality of life

Dosing Regimen

• Dose: 25-50 mg oral DHEA
• Timing: Single dose in the morning
• Trial duration: 6 months 2
• Decision point: If no sustained beneficial effect after 6 months, discontinue DHEA 2

Monitoring Parameters

• Morning serum DHEAS levels (before taking daily dose)
  • Target: Mid-normal range for premenopausal women
  • Frequency: Periodically during treatment 2
• Clinical response: Libido, mood, energy levels, depressive symptoms
• Adverse effects: Acne, hirsutism, voice changes, other androgenic effects
• Body weight and blood pressure: Monitor for signs of excess

Evidence Limitations

A systematic review and meta-analysis found insufficient evidence to support routine DHEA use in adrenal insufficiency, with inconsistent benefits across studies. 2 Some studies show improvement in quality of life, mood, and sexual function, while others show no benefit. 8, 9 This explains the weak recommendation grade and the requirement for a time-limited trial with clear discontinuation criteria.

---

Contraindications and Situations Where DHEA Should NOT Be Used

The Endocrine Society explicitly recommends AGAINST routine DHEA use in the following scenarios: 1

General Population

• Healthy women without adrenal insufficiency - no defined androgen deficiency syndrome exists
• Infertility treatment
• Sexual dysfunction other than hypoactive sexual desire disorder
• Cognitive enhancement
• Cardiovascular health
• Metabolic health or diabetes
• Bone health or osteoporosis prevention
• General well-being or "anti-aging"

Specific Conditions with Low Androgens

DHEA is NOT routinely recommended even when androgen levels are low in:

• Hypopituitarism
• Secondary adrenal insufficiency
• Surgical menopause
• Glucocorticoid therapy
• Other conditions with documented low androgen levels

The rationale: Limited data on effectiveness, no long-term safety studies, and lack of correlation between androgen levels and symptoms. 1

---

Critical Pitfalls and Caveats

Over-the-Counter Availability Risk

DHEA is sold as a dietary supplement in many countries, leading to widespread unregulated use. 2 This creates several problems:

• Variable product quality and actual DHEA content
• Self-medication without appropriate indication
• Lack of medical supervision and monitoring
• Potential androgenic side effects going unrecognized

Gender-Specific Effects

DHEA shows markedly different effects by sex. In women, DHEA increases testosterone and androstenedione levels; in men, it does not significantly increase testosterone but may decrease SHBG. 9 This explains why evidence supports use primarily in women with adrenal insufficiency.

Pregnancy Considerations

While not explicitly contraindicated, there are no adequate safety data for DHEA use during pregnancy. The adrenal insufficiency guidelines focus on hydrocortisone dosing during pregnancy without mentioning DHEA continuation. 2

Metabolic Effects Are Inconsistent

Despite some studies showing improvements in cholesterol (particularly in Addison's disease) and body fat percentage, these effects are not consistent enough to justify DHEA use for metabolic indications. 9

No Role in Male Sexual Dysfunction

Despite marketing claims, clinical trials have not shown consistent benefits for male sexual dysfunction. 8 DHEA should not be prescribed for this indication.

---

Practical Clinical Algorithm

For postmenopausal women with dyspareunia:

1. Confirm moderate-to-severe dyspareunia due to vulvovaginal atrophy
2. Prescribe intravaginal prasterone 6.5 mg daily
3. Assess response at 4 weeks
4. Continue if beneficial; no routine lab monitoring needed
5. Monitor for vaginal discharge and local irritation

For women with primary adrenal insufficiency and persistent symptoms:

1. Confirm PAI diagnosis and optimize glucocorticoid/mineralocorticoid replacement first
2. Document persistent low libido, depression, or fatigue affecting quality of life
3. Initiate oral DHEA 25-50 mg each morning
4. Check morning DHEAS level (before dose) after 4-6 weeks, adjust to mid-normal range
5. Assess clinical response at 3 and 6 months
6. If no sustained benefit by 6 months, discontinue
7. If beneficial, continue with periodic DHEAS monitoring and clinical assessment

For all other indications: Do not prescribe DHEA. 1